(NASDAQ: CTKB) Cytek Biosciences's forecast annual revenue growth rate of 34.23% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 90.93%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Cytek Biosciences's revenue in 2023 is $164,036,000.On average, 2 Wall Street analysts forecast CTKB's revenue for 2023 to be $29,820,062,807, with the lowest CTKB revenue forecast at $29,574,527,085, and the highest CTKB revenue forecast at $30,065,598,528.
In 2024, CTKB is forecast to generate $37,490,040,766 in revenue, with the lowest revenue forecast at $35,970,373,734 and the highest revenue forecast at $39,009,707,798.